Sanofi's (SASY.PA) candidate drug Lyxumia or lixisenatide, added to basal insulin, significantly reduced blood sugar levels in type 2 diabetes patients and also led to a loss in weight, data published on Tuesday showed.
Lixisenatide belongs to the GLP-1 class of drugs that stimulate insulin release when glucose levels become too high.
